Barbiturates can induce hepatic microsomal enzymes causing amplified metabolism and lowered anticoagulant reaction of oral anticoagulants (eg, warfarin, acenocoumarol, dicumarol, and phenprocoumon); patients stabilized on anticoagulant therapy might have to have dosage adjustments if barbiturates are added to or withdrawn from their dosage routine
pentobarbital will lower the extent or outcome of diclofenac by influencing hepatic enzyme CYP2C9/ten metabolism. Small/Significance Unknown.
pentobarbital will lessen the level or effect of disopyramide by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Significance Unidentified.
pentobarbital will lower the extent or effect of fentanyl transmucosal by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Observe Carefully. Coadministration of fentanyl with CYP3A4 inducers could lead on to some lessen in fentanyl plasma concentrations, lack of efficacy or, potentially, development of a withdrawal syndrome inside of a individual who has formulated physical dependence to fentanyl.
pentobarbital will minimize the extent or result of atorvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
CYP3A4 inducers could raise the formation of the neurotoxic/nephrotoxic ifosfamide metabolite, chloroacetaldehyde. Intently check clients getting ifosfamide with CYP3A4 inducers for toxicities and think about dose adjustment.
pentobarbital will decrease the level or result click here of estropipate by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on.
pentobarbital will lessen the level or outcome of paclitaxel by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Mysterious.
This drug might raise the metabolism of estradiol when administered concurrently; individuals on oral contraceptives have grown to be Expecting when concurrently dealt with with antiepileptic medications; advise an alternate contraceptive technique to Ladies having this drug
pentobarbital will minimize the level or result of cobimetinib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Steer clear of coadministration. Powerful or moderate CYP3A inducers may possibly lower cobimetinib systemic publicity by >eighty% and lower its efficacy.
Extended or recurring exposure could lead to destructive consequences on fetal or youthful young children’s Mind growth
pentobarbital will decrease the level or impact of atogepant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Check Carefully. Advisable atogepant dosage with concomitant use of robust or reasonable CYP3A4 inducers is thirty mg or sixty mg qDay.
pentobarbital will reduce the extent or outcome of nitrendipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Mysterious.
pentobarbital will lower the extent or impact of bosentan by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Significance Unidentified.